A History of Biopharmaceutics in the Food and Drug Administration 1968–1993
Journal Title: The AAPS Journal - Year 2010, Vol 12, Issue 1
Abstract
The history of biopharmaceutics is reviewed, beginning with its origin out of the Division of Clinical Research in The Bureau of Medicine. The reason for the creation of the Division of Biopharmaceutics, the certification of Food and Drug Administration authority over the functions it was to have, and the implementation of that authority are described. The determination of bioequivalence, the bioavailability decision rules, pharmacokinetics, and drug metabolism are explained. The reason for the development of the Scale-Up and Post Approval Regulations and how they were developed are also explained.
Authors and Affiliations
Jerome Philip Skelly
Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions
Drug-induced hypersensitivity reactions are instructive examples of immune reactions against low molecular weight compounds. Classically, such reactions have been explained by the hapten concept, according to which the s...
Model-Based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor
The online version of this article (doi:10.1208/s12248-011-9254-0) contains supplementary material, which is available to authorized users.
A Bayesian Approach for Quantifying Trace Amounts of Antibody Aggregates by Sedimentation Velocity Analytical Ultracentrifugation
Sedimentation velocity analytical ultracentrifugation (SV-AUC) has become an important tool for the characterization of the purity of protein therapeutics. The work presented here addresses a need for methods orthogonal...
Preparation and ocular pharmacokinetics of ganciclovir liposomes
Ophthalmic liposomes of ganciclovir (GCV) were prepared by the reverse phase evaporation method, and their ocular pharmacokinetics in albino rabbits were compared with those obtained after dosing with GCV solution. The i...
Determination of carryover and contamination for mass spectrometry-based chromatographic assays
The Third American Association of Pharmaceutical Scientists/Food and Drug Administration Bioanalytical Workshop, held in 2006, reviewed and evaluated current practices and proposed that carryover and contamination be ass...